NASDAQ:YMTX

Yumanity Therapeutics - YMTX Stock Forecast, Price & News

$7.00

-0.83 (-10.60%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $7.00
▼
$8.22
50-Day Range: $1.68
▼
$7.83
52-Week Range: $0.95
▼
$3.78

Volume: 15,023 shs
Average Volume: 473,083 shs
Market Capitalization: $75.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Yumanity Therapeutics (NASDAQ:YMTX) Stock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Stock News Headlines

December 26, 2022 | msn.com

Yumanity Therapeutics's Return On Capital Employed Insights

December 20, 2022 | bizjournals.com

Kineta finalizes reverse merger with Yumanity, secures additional funding

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

December 5, 2022 | finance.yahoo.com

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

December 5, 2022 | investorplace.com

Why Is Yumanity Therapeutics (YMTX) Stock Up Today?

November 14, 2022 | finanznachrichten.de

Yumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 14, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

August 29, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

August 4, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

June 8, 2022 | finance.yahoo.com

Inside Kineta's plans after unveiling reverse merger deal

June 7, 2022 | bizjournals.com

Seattle biotech Kineta to go public in merger deal with Yumanity Therapeutics

June 7, 2022 | msn.com

Short Volatility Alert: Yumanity Therapeutics, Inc.

June 6, 2022 | marketwatch.com

Yumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTX

June 6, 2022 | seekingalpha.com

Yumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26M

June 6, 2022 | nasdaq.com

Yumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With Kineta

June 6, 2022 | finance.yahoo.com

Yumanity Therapeutics Shares Trading Higher Today - Read Here Why

June 6, 2022 | investorplace.com

Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?

June 6, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

June 2, 2022 | benzinga.com

53 Stocks Moving In Thursday's Mid-Day Session

May 14, 2022 | seekingalpha.com

Yumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02M

May 13, 2022 | finance.yahoo.com

Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

March 25, 2022 | benzinga.com

Looking Into Yumanity Therapeutics's Return On Capital Employed

March 24, 2022 | seekingalpha.com

Yumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04M

March 24, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Company Calendar

Last Earnings: 8/12/2021
Today: 1/28/2023
Next Earnings (Estimated): 3/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:YMTX
CUSIP: N/A
CIK: 1445283
Web: www.yumanity.com
Phone: (617) 409-5300
Fax: N/A
Employees: 40
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,500,000.00
Net Margins: -660.61%
Pretax Margin: -660.61%
Return on Equity: -263.34%
Return on Assets: -107.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.21
Quick Ratio: 2.21

Sales & Book Value

Annual Sales: $8.04 million
Price / Sales: 9.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.28 per share
Price / Book: 3.07

Miscellaneous

Outstanding Shares: 10,856,000
Free Float: 9,504,000
Market Cap: $75.99 million
Optionable: Not Optionable
Beta: 0.32

Key Executives

Dr. Richard Peters M.D. (Age 59)
Ph.D., CEO, Pres & Director
Comp: $896.1k

Dr. Vikram Khurana M.D.
Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology

Ms. Chee Yeun Chung Ph.D.
Scientific Co-Founder & Associate Director of Discovery Biology

Ms. Marie Epstein CPA
VP of Fin.

Mr. Michael D. Wyzga (Age 33)
SVP, CFO & Treasurer

Mr. Devin Whittemore Smith (Age 54)
SVP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

YMTX Stock - Frequently Asked Questions

How have YMTX shares performed in 2023?: Yumanity Therapeutics' stock was trading at $6.35 at the start of the year. Since then, YMTX shares have increased by 10.2% and is now trading at $7.00.
View the best growth stocks for 2023 here.
When is Yumanity Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our YMTX earnings forecast.
How were Yumanity Therapeutics' earnings last quarter?: Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

What is Yumanity Therapeutics' stock symbol?: Yumanity Therapeutics trades on the NASDAQ under the ticker symbol "YMTX."
How do I buy shares of Yumanity Therapeutics?: Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Yumanity Therapeutics' stock price today?: One share of YMTX stock can currently be purchased for approximately $7.00.
How much money does Yumanity Therapeutics make?: Yumanity Therapeutics (NASDAQ:YMTX) has a market capitalization of $75.99 million and generates $8.04 million in revenue each year. The company earns $-39,500,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.
How can I contact Yumanity Therapeutics?: Yumanity Therapeutics' mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The official website for the company is www.yumanity.com. The company can be reached via phone at (617) 409-5300 or via email at lroth@burnsmc.com.

This page (NASDAQ:YMTX) was last updated on 1/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial